为您找到相关结果约500个

你是不是要搜索 期刊Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab 点击跳转

Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab

First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in

HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global

Biosimilar Trastuzumab in Clinical Trials: Differences or Not?

Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China

Efficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer

A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs.EU-trastuzumab and US-trastuzumab

A multicenter real-world study comparing the clinical equivalence of trastuzumab biosimilar HLX02 andreference trastuzumab in the treatment of HER-2-positive breast cancer

Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumabin metastatic breast cancer: A global phase III study

ABP 980: A Trastuzumab Biosimilar

Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar

PF-05280014: A Trastuzumab Biosimilar

SB3 (Ontruzant (R)): A Trastuzumab Biosimilar

FDA Approves Trastuzumab Biosimilar

Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in

为您找到相关结果约500个

共500条页码: 1/34页15条/页